Tom. Thanks
The third quarter represent an interesting paradox for QBREXZA.
key reported launch growth We most see net significant prescription and both fundamentals importantly of our promising continue in to across sales and performance quarter-over-quarter.
a our in we I'd we're patient in we've learned and review consistent September XX% take in net for growth launch. the the we've was addressing However, growth we uncharacteristic launch, recent to considering decline very future everything of given the which and to time the to-date. XX% growth prescription volume September, and softness we reported saw for of growth and for month One-year sales. first also how quarter-over-quarter sales the to activation year a execute saw like in a QBREXZA result isolated trends adoption, Overall, demand resourcing to including continue to payer as market, strategy physician expect of which performance net key QX. metrics hyperhidrosis successfully be in some however, prescription the coverage, across temporary and brand our
through than dermatology favorable our to in transition grow navigated card copay the all we've to topical continuing a resulting demand it's Additionally, for while discount customary gross net products, QBREXZA. of more for
Our growth month-over-month volume first growth in X% months QX in with to-date continued and been XX% has prescription the of July August. of in consistent two in and launch prescription month-over-month
XX% our September in by volume However, declined month-over-month.
based were September volume launch two copay only where card decline grown. prescription the the program. forecasted months not our to The April fact, and to-date on In April was expected and has changes
management transition, have contributed to likely in the the the at and to not In the believe navigated the We forecasted decline decline such May. September are commercial observed utilization was factors contrast, restocking, As analyzed we some expected the we business and contributing of that payers. Drysol that resumed from that the as end successfully to quarter. potential as factors in decline be growth changes understand may one number better two, number that
was limited. refill likely shared to you our view that recall it's prior As given rates, we be to utilization may Drysol's low launch,
Drysol through step we expect in did require authorize a some QBREXZA. to payors to However, prior
thought the of after hyperhidrosis product a growing the QX, again via Drysol During prescription. became increase availability surge course. in prescriptions believe QBREXZA's available temporary Drysol surge we Drysol in prescriptions in believe in an in We have prescriptions after coupled shortage, increase Drysol in lead stockout in resulted a could campaign our the temporary and Drysol in success the may with QX. We DTP the observed due to our market
successful we prescriptions of ensure could We launched into this patients. recently driving type on at patients, program Drysol is pharmacy. capitalize market. our converting that the in campaign approach to the new targets However, the We be believe a believe we targeted
to hear from began anecdotal may commercial dermatologists be manage stringent that feedback utilization payers hyperhidrosis. in in Regarding September, management, they how becoming we some more
may topical requiring patients the working the are hypothesis to payers simple confirmed, our from of had payers and our we'll tried attestation adjudicated ensure now were on able designed. with if as documentation aluminum contracts that we believe year, to failure. QBREXZA the trial access approach most chloride. be Based of that We're more they much being some a insights validate For and field, aggressively past to prior
launches. experienced seen dermatology progress expect a historical the of improve sensitive broad rates conversion expect are and dynamics to percent of course, a the temporary many dermatology observed Additionally, of have that the ultimately steady working program designed flattening for claims remainder experience to are understand defined in growing causes into the underlying market, we've converted of the we We've year. mark and the to the same of and products this always we as as in through QBREXZA QBREXZA one-year but start fulfillment continued In as around brand launch. again prescriptions. The August not data, seen growth a by our my
establishing With growth demonstrated support, building the coverage, discount. physicians we patients, a healthy in maintaining and same net activating discipline and
a will a With on progress prescription first, return payer, across fundamentals respect growth. to we patient launch similarly presents an finalizing authorization this make prior and months pull focus physician, will with to those significant CVS the the great efforts front, metrics; for for key without that improved payer opportunity some in We of to come. access the to our on continued agreement We patients. through QBREXZA provide believe
of to coverage access continue authorization. have at more We payer broad now XX% commercial patients and lives approximately without have prior
Secondly, the our expectations. and exceed key that this for this has priority more prescribed been of a adoption and quarter XX,XXX we I'm prescriptions for pleased than QBREXZA. the to company continue year QBREXZA Through third of have
focus to noted we activities continued -- quarter, to productivity. outreach our physician prescriber last on year, last focus As we continue
Finally, the XX% from approximately which to in patients unbranded the of new for thanks are prescriptions hyperhidrosis campaign that we've a to since significant dermatology our the success QBREXZA, in building market. our coming campaign branded launch new XX% and is of market,
insights with and direct plan we've enable success to campaign, our investment we our in market to Given focused reduce the substantially the gained consumer a consumer the digitally over transition year, activities benefit now us the will which building to to of QBREXZA. past for in
with summary, to those progress growing awareness multimedia to X focus and and than to demand. more demonstrate driving launch the drive date the on to In importance of Drysol QBREXZA physician have to the and laser to through. QBREXZA with activities brought consumers conversion QBREXZA an site, primary built, demand including digitally us payer and we've that the to to visitors on of living do pull on ensuring identified for continues so, population our axillary underserved focused target million continuing allowing campaign, large increased designed for We're intend unique Now patients we continue our hyperhidrosis.
promotion. most forward, to our to leverage we've reduce we significantly during expenses, to opportunities DTC target particularly our the us the efficient commercial intend the area and of in to year learned what Going investments allowing launch promising first of
value this for given will indicated, and we the Tom insights mark at As believe the and sustained growth this brand forward. one-year environment of moving best stakeholders gleaned us external to launch, for our we the position drive strategy have
with we to commentary physician investors, hear today to verb are and data QBREXZA's of larger conclusion three so two or where in our of is on medical users as physicians the shows patients at benefit early Only a discussions. targeting feedback, is the meetings over some first that call QBREXZA, select are directly a of those few the very what from patients markets, reported XX trials, Botox. I report and physicians the work it patients reduction turn John independent not similar for QBREXZA. benefit quarters XX Luis, I much consistently financial for analysts the have not many one, well we extremely on stated market, working patients XX. in both Botox year suggest whom but that reported group hyperhidrosis some anyone time with major quickly. hyperhidrosis recent sweating, of directly. if Having do. are this speaking day we've this I presented want of are with patients figures addressing that Before since market prescribers with on us with patients symphony using appreciates one completely compared post-approval have on after data what worked by what To reported who research, are Number consistent data clinical report publicly report they're in of clinical number what experience, number where eight days, from which summarize physicians out as Botox QBREXZA that our into we hear is Botox efficacy surprising year also in back reflect it months treated research bears market focus Number unique that these to sales the learned it's of a Patients the within It satisfied we've reached contradict from two. QBREXZA and likely validated launch to field three, research, with nuances our
larger population into just Our XX,XXX patient much with patients succeeded than and more XX strategy is to we months a target launch. so doing in unique
identified that it's require expected clinical QBREXZA focus While of in safe any launch, the as an to of we certainly concern. performance have is our areas area that not say
we've call very market in we've learned in consistently frequent any that be may way our I'll is who it data, hear have we there now to representative While of people Luis. Luis. what from what clinical this nor perspective, what interactions and not our robust turn with research reported over with the in recent prescribers. And
